10.13.11
Subramanyam Maddala has been appointed president of India operations at AMRI. Mr. Maddala assumes leadership for the company’s Indian API manufacturing operations as well as responsibility for AMRI facility operations in Hyderabad and Aurangabad, India. He reports to Dr. Steven Hagen, AMRI’s vice president of pharmaceutical development and manufacturing.
Mr. Maddala has more than 20 years of operations, business development, and senior leadership experience in the manufacturing of APIs and intermediates, custom synthesis, and formulations in branded and generics markets. Most recently, he served as vice president, Contract Research and Manufacturing Services (CRAMS) and New Generics for Shasun Pharmaceuticals Ltd., and was responsible for its contract research and manufacturing business, including all vertical CRAMs businesses and new API generic efforts. Prior to that, Mr. Maddala held several roles of increasing responsibility at firms including Piramal India Ltd., Glenmark Pharmaceuticals, Medicorp/Matrix Labs, Torrent Pharmaceuticals, SOL and Lupin Laboratories.
“We are pleased to welcome Mr. Maddala to the AMRI leadership team and believe he is the right person to take AMRI’s chemical manufacturing business in India to the next level, including the capability to eventually manufacture multiple products in India to U.S. FDA standards,” said Dr. Hagen.
Mr. Maddala has more than 20 years of operations, business development, and senior leadership experience in the manufacturing of APIs and intermediates, custom synthesis, and formulations in branded and generics markets. Most recently, he served as vice president, Contract Research and Manufacturing Services (CRAMS) and New Generics for Shasun Pharmaceuticals Ltd., and was responsible for its contract research and manufacturing business, including all vertical CRAMs businesses and new API generic efforts. Prior to that, Mr. Maddala held several roles of increasing responsibility at firms including Piramal India Ltd., Glenmark Pharmaceuticals, Medicorp/Matrix Labs, Torrent Pharmaceuticals, SOL and Lupin Laboratories.
“We are pleased to welcome Mr. Maddala to the AMRI leadership team and believe he is the right person to take AMRI’s chemical manufacturing business in India to the next level, including the capability to eventually manufacture multiple products in India to U.S. FDA standards,” said Dr. Hagen.
